GlassScriptPhysician profile
Jesus A Lopez
NPI 1861543332
$8,050.30
in general payments reported to CMS, 2019-2025
39 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $1,020 · 2021: $1,063 · 2022: $1,107 · 2023: $1,342 · 2024: $1,182 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,016 · Gift: $59.40 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,015.94 |
| Gift | $59.40 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,659.83 | 2021-2025 | Caplyta |
| Amgen INC. | $687.01 | 2020-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $661.43 | 2020-2025 | Mounjaro, Jardiance |
| Sunovion Pharmaceuticals INC. | $601.21 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $532.48 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Mannkind Corporation | $484.80 | 2019-2023 | Afrezza |
| Pfizer INC. | $345.09 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $342.33 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.70 | 2019-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $315.58 | 2019-2025 | Austedo Xr, Uzedy, Ajovy |
| Glaxosmithkline, LLC. | $295.02 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $287.06 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $223.12 | 2022-2025 | Hetlioz, Fanapt, Ponvory |
| Shield Therapeutics INC | $184.45 | 2023-2024 | Accrufer |
| Ucb, INC. | $161.53 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.